CD274抗体,Mouse Monoclonal CD274 Antibody
  • CD274抗体,Mouse Monoclonal CD274 Antibody
  • CD274抗体,Mouse Monoclonal CD274 Antibody
  • CD274抗体,Mouse Monoclonal CD274 Antibody

CD274抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-10
QQ交谈 微信洽谈

产品详情

中文名称:CD274抗体英文名称:Mouse Monoclonal CD274 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 865 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD274
2025-05-10 CD274抗体 Mouse Monoclonal CD274 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 865 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesB7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
Entrez GeneID29126
clone7D2A10
WB Predicted band size33.3kDa
Host/IsotypeMouse IgG2b
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD274 (AA: 24-153) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of Hela cells using CD274 mouse mAb (green) and negative control (red).    


           

参考文献

以下是关于CD274(PD-L1)抗体的3篇模拟参考文献示例(非真实文献,仅供格式参考):

---

1. **文献名称**: *"Targeting PD-L1 for Cancer Immunotherapy: Mechanisms and Clinical Progress"*

**作者**: Smith A, et al.

**摘要**: 本文综述了PD-L1抗体在肿瘤免疫治疗中的作用机制,包括阻断PD-1/PD-L1通路以恢复T细胞活性,并总结了多项临床试验中抗PD-L1单抗(如Atezolizumab)在非小细胞肺癌和黑色素瘤中的疗效与安全性。

2. **文献名称**: *"Structural Basis of PD-L1 Recognition by Therapeutic Antibodies"*

**作者**: Zhang Y, et al.

**摘要**: 通过X射线晶体学解析了PD-L1蛋白与多种治疗性抗体的结合表位,揭示了抗体通过空间位阻效应阻断PD-1/PD-L1相互作用的分子机制,为优化抗体设计提供了结构学依据。

3. **文献名称**: *"PD-L1 Expression as a Predictive Biomarker for Anti-PD-L1 Therapy Response"*

**作者**: Johnson R, et al.

**摘要**: 研究探讨了肿瘤组织PD-L1表达水平与抗PD-L1抗体治疗反应的相关性,发现高表达患者客观缓解率显著提高,但部分低表达患者仍可受益,提示需结合其他生物标志物优化治疗方案。

---

(注:如需真实文献,可检索PubMed等数据库,关键词如“anti-PD-L1 antibody”、“CD274 immunotherapy”。)

       

背景信息

CD274. also known as programmed death-ligand 1 (PD-L1), is a transmembrane protein belonging to the B7 family of immune checkpoint molecules. It plays a critical role in modulating immune responses by binding to its receptor PD-1 (programmed cell death protein 1) on T cells, thereby suppressing T-cell activation and promoting immune tolerance. Tumors often exploit this pathway by overexpressing PD-L1 to evade immune surveillance, enabling uncontrolled growth and metastasis. Targeting the PD-1/PD-L1 axis has emerged as a groundbreaking strategy in cancer immunotherapy.

CD274 antibodies are monoclonal antibodies designed to block the interaction between PD-L1 and PD-1. effectively "releasing the brakes" on T cells and restoring their anti-tumor activity. Since the first FDA approval of anti-PD-L1 agents like atezolizumab (2016), durvalumab, and avelumab, these therapies have transformed treatment paradigms for various cancers, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. Beyond oncology, PD-L1 antibodies are being explored in infectious diseases and autoimmune conditions due to their immunoregulatory properties.

Clinically, CD274 antibodies are often used as monotherapy or combined with chemotherapy, radiation, or other immunotherapies. Their efficacy correlates with tumor PD-L1 expression levels, which are assessed via companion diagnostic assays. However, challenges persist, including variable response rates, acquired resistance, and immune-related adverse events. Ongoing research focuses on optimizing patient selection, identifying predictive biomarkers, and developing next-generation agents with improved safety profiles.

       
关键字: CD274抗体;CD274;CD274 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
普通会员
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

CD274抗体相关厂家报价

产品名称 价格   公司名称 报价日期
¥1180
VIP1年
上海西格生物科技有限公司
2026-02-24
¥1180
VIP1年
上海博湖生物科技有限公司
2026-02-24
¥1180
VIP1年
上海抚生实业有限公司
2026-02-24
询价
湖北艾普蒂生物工程有限公司
2024-02-21
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.